Molecular Diagnostics Market Size, Share, Trend, Industry Analysis Report By Product (Instruments, Reagents, Others), By Test Location, By Technology, By Application, By Region – Market Forecast, 2025–2034

The molecular diagnostics market size is expected to reach USD 38.01 billion by 2034, according to a new study by Polaris Market Research. The report “Molecular Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Reagents, Others), By Test Location, By Technology, By Application, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The molecular diagnostics market focuses on the use of molecular biology techniques to detect genetic material, proteins, or other specific biomarkers in a patient’s sample, enabling precise diagnosis, prognosis, and monitoring of diseases. This market has grown significantly due to the increasing demand for accurate, rapid, and minimally invasive diagnostic methods that support personalized medicine. The rising prevalence of infectious diseases, cancer, and genetic disorders has accelerated the adoption of molecular diagnostics in clinical settings. Continuous advancements in technologies such as digital PCR, next-generation sequencing, and microarrays are improving test sensitivity, specificity, and turnaround times, enhancing clinical decision-making.

Growing awareness among healthcare providers and patients about early disease detection is driving wider usage in preventive care. The integration of AI and automation in testing platforms is streamlining workflows and reducing errors, improving efficiency in laboratories. Expansion of point-of-care molecular testing is making diagnostics more accessible and timely, particularly in urgent care situations. Increasing investments in research and development by diagnostic companies is leading to innovative assays and platforms with broader test menus. Industry trends include a shift toward decentralized testing models, growth in companion diagnostics for targeted therapies, and rising collaborations between diagnostic developers and pharmaceutical companies. Opportunities lie in expanding test portfolios to address emerging pathogens, leveraging digital health integration for remote diagnostics, and advancing multiplex testing to detect multiple conditions in a single run. The market is positioned for sustained growth as precision medicine continues to shape healthcare, demanding fast, accurate, and scalable diagnostic solutions.

Molecular Diagnostics Market Report Highlights

By product, the reagents systems segment dominated the market with ~66% of the revenue share due to continuous demand for consumables in routine molecular diagnostic workflows.

Based on test location, the central laboratories segment held ~80% of the revenue share in 2024 due to their capability to process high testing volumes with advanced instrumentation and specialized expertise.

The North America molecular diagnostics market accounted for the largest revenue share of ~41% due to strong adoption of advanced molecular testing technologies, and supported by a well-established healthcare infrastructure.

The Asia Pacific market is expected to grow significantly during 2025–2034 due to increasing healthcare investments, rapid adoption of advanced diagnostic platforms, and the rising burden of chronic and infectious diseases.

A few global key players include Abbott; Agilent Technologies, Inc.; BD; BIOMÉRIEUX; Bio-Rad Laboratories, Inc.; Danaher; F. Hoffmann-La Roche, Ltd.; Grifols; Hologic Inc. (Gen Probe); Illumina, Inc.; QIAGEN; Siemens Healthineers AG; and Sysmex Corporation.

Polaris Market Research has segmented the molecular diagnostics market report on the basis of product, test location, technology, application, and region:

By Product Outlook (Revenue, USD Billion, 2020–2034)

Instruments

Reagents

Others

By Test Location Outlook (Revenue, USD Billion, 2020–2034)

Point of Care

Self-test or OTC

Central Laboratories

By Technology Outlook (Revenue, USD Billion, 2020–2034)

Polymerase Chain Reaction (PCR)

PCR, by Procedure

Nucleic Acid Extraction

Others

PCR, by Type

Multiplex PCR

Other PCR

PCR, by Product

Instruments

Reagents

Others

In Situ Hybridization (ISH)

Isothermal Nucleic Acid Amplification Technology (INAAT)

Chips and Microarrays

Mass Spectrometry

Transcription Mediated Amplification (TMA)

Others

By Application Outlook (Revenue, USD Billion, 2020–2034)

Oncology

Pharmacogenomics

Infectious Disease

MRSA

Clostridium Difficile

Tuberculosis and Drug-Resistant TB

Meningitis

Gonorrhea

HIV

Hepatitis C

Hepatitis B

Others

Genetic Testing

Neurological Disease

Cardiovascular Disease

Microbiology

Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa Show more